MorphoSys Backs Dutch Firm Lanthio in $6M Series A Round

Lanthio Pharma BV found an influential backer for its peptide technology in the shape of antibody developer MorphoSys AG, which has participated in its €4.8 million (US$6.2 million) Series A round and which will help it to develop and commercialize its LanthioPep platform.